Literature DB >> 30759233

Massive Ovarian Growth in a Woman With Severe Insulin-Resistant Polycystic Ovary Syndrome Receiving GnRH Analogue.

Prapti Singh1, Ariela Agress2, Vanessa Kasarah Madrigal2, Clara Magyar3, Nora Ostrzega3, Gregorio Daniel Chazenbalk2, Daniel Anthony Dumesic2.   

Abstract

CONTEXT: Ovarian hyperandrogenism from polycystic ovary syndrome (PCOS) and hyperinsulinemia from insulin resistance are modulators of ovarian follicle development. We report on a woman with PCOS and hyperandrogenism and severe insulin resistance from metabolic syndrome who received long-term GnRH analogue therapy preceding bilateral salpingo-oophorectomy for massive ovarian enlargement. Ovarian histological examination showed proliferating granulosa cells within antral follicles coexistent with serous cystadenofibromas, demonstrating a unique link between hyperinsulinemia and granulosa cell mitogenesis. CASE DESCRIPTION: A 30-year-old woman with PCOS with hyperandrogenism, severe insulin resistance from metabolic syndrome, and nonalcoholic steatohepatitis experienced abdominal pain from bilaterally enlarged ovaries. She had previously experienced a pulmonary embolism while taking oral contraceptives and hepatotoxicity from metformin and spironolactone therapies. Long-term GnRH analogue therapy to induce pituitary desensitization to GnRH successfully decreased gonadotropin-dependent steroidogenesis without improving insulin resistance. Despite GnRH analogue therapy, progressive ovarian enlargement in the presence of hyperinsulinemia from worsening metabolic function eventually required bilateral salpingo-oophorectomy for removal of massively enlarged ovaries. Histological examination showed both ovaries contained proliferating granulosa cells within antral follicles coexistent with serous cystadenofibromas.
CONCLUSIONS: In women with PCOS and hyperinsulinemia from severe insulin resistance due to metabolic syndrome, granulosa cell proliferation within antral follicles can occur despite long-term GnRH analogue therapy, implicating hyperinsulinemia as a granulosa cell mitogen in the absence of gonadotropin-dependent ovarian function.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30759233      PMCID: PMC6894611          DOI: 10.1210/jc.2018-02464

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Ovarian cystadenofibroma: a consideration of the role of estrogen in its pathogenesis.

Authors:  L Papadaki; J O Beilby
Journal:  Am J Obstet Gynecol       Date:  1975-02-15       Impact factor: 8.661

2.  Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth.

Authors:  Carla Musso; Thomas Shawker; Elaine Cochran; Edward D Javor; Janice Young; Phillip Gorden
Journal:  Clin Endocrinol (Oxf)       Date:  2005-07       Impact factor: 3.478

3.  A huge ovarian mucinous cystadenoma associated with contralateral teratoma and polycystic ovary syndrome in an obese adolescent girl.

Authors:  Patcharapa Thaweekul; Yuthadej Thaweekul; Karicha Mairiang
Journal:  Asia Pac J Clin Nutr       Date:  2016-12       Impact factor: 1.662

4.  P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.

Authors:  Nesrin Gursan; Sare Sipal; Muhammed Calik; Cemal Gundogdu
Journal:  Eurasian J Med       Date:  2009-04

Review 5.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

6.  Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.

Authors:  G G Garzetti; A Ciavattini; G Goteri; M De Nictolis; D Stramazzotti; G Lucarini; G Biagini
Journal:  Gynecol Oncol       Date:  1995-02       Impact factor: 5.482

7.  Granulosa cell survival and proliferation are altered in polycystic ovary syndrome.

Authors:  M Das; O Djahanbakhch; B Hacihanefioglu; E Saridogan; M Ikram; L Ghali; M Raveendran; A Storey
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

8.  Insulin but not insulin-like growth factor-1 promotes the primordial to primary follicle transition.

Authors:  Phillip R Kezele; Eric E Nilsson; Michael K Skinner
Journal:  Mol Cell Endocrinol       Date:  2002-06-28       Impact factor: 4.102

9.  Insulin resistance enhances the mitogen-activated protein kinase signaling pathway in ovarian granulosa cells.

Authors:  Linghui Kong; Qien Wang; Jiewen Jin; Zou Xiang; Taoyu Chen; Shanmei Shen; Hongwei Wang; Qian Gao; Yong Wang
Journal:  PLoS One       Date:  2017-11-10       Impact factor: 3.240

10.  Type B Insulin Resistance Masquerading as Ovarian Hyperthecosis.

Authors:  Rebecca J Brown; Jalaja Joseph; Elaine Cochran; Cornelia Gewert; Robert Semple; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2017-06-01       Impact factor: 5.958

View more
  3 in total

1.  Reversible severe ovarian enlargement in an infant with significant insulin resistance.

Authors:  Lai Lillian; Mikhchi Amir; Ryabets-Lienhard Anna; Geffner Mitchell E; Cheung Clement; Giuffre Danielle
Journal:  Radiol Case Rep       Date:  2021-05-01

2.  Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance.

Authors:  Isabel Huang-Doran; Alexandra B Kinzer; Mercedes Jimenez-Linan; Kerrie Thackray; Julie Harris; Claire L Adams; Marc de Kerdanet; Anna Stears; Stephen O'Rahilly; David B Savage; Phillip Gorden; Rebecca J Brown; Robert K Semple
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

3.  Association of Angiotensin-Converting Enzyme gene polymorphism in Pakistani women with the atypical steroidogenesis in Polycystic ovarian syndrome: A case-control study.

Authors:  Kiran Nazeer; Nasira Munawar Lone; Shumaila Sadique; Sikandar Sultan; Amna Zia Eupash; Saba Riaz
Journal:  Saudi J Biol Sci       Date:  2021-03-14       Impact factor: 4.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.